Regulatory News Service

ENOGIA, leader of the QualifHY consortium, a collaborative research project on Hydrogen

Friday, December 3, 2021 - 5:06pm

ENOGIA, leader of the QualifHY consortium, a collaborative research project on Hydrogen

Key Points: 
  • ENOGIA, leader of the QualifHY consortium, a collaborative research project on Hydrogen
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • ENOGIA, leader of the QualifHY consortium,
    Marseille, 3 December 2021 - 6.00 p.m.
    ENOGIA, an expert in micro-turbomachinery for the energy transition, announces its participation as leader alongside three key players in the hydrogen sector in the QualifHY consortium.
  • The purpose of this research project is to develop a shared platform for testing, qualifying and characterising hydrogen components, systems and industrial processes for fuel cells.
  • This collaborative project creates a real regional ecosystem around Hydrogen, and more particularly the fuel cell, an element identified as key to the energy transition.

Waga Energy and Meridiam secure refinancing of four biomethane units from French banks consortium

Friday, December 3, 2021 - 8:01am

The WAGABOX(R) units are part of two SPV companies, one of which is jointly owned by Meridiam.

Key Points: 
  • The WAGABOX(R) units are part of two SPV companies, one of which is jointly owned by Meridiam.
  • These two companies signed a non-recourse credit agreement with the banks for 10.4 million euros to repay the loans previously contracted with Waga Energy and Meridiam.
  • The refinancing of these four WAGABOX(R) units will strengthen Waga Energy's cash flow and enable further financing of new projects in Europe and North America.
  • The SPV company jointly owned by Waga Energy and Meridiam hosts three biomethane units, one of which is still under construction.

COMPAGNIE MERCOSUR GRECEMAR: COMPAGNIE MERCOSUR GRECEMAR (CMG) ACQUIRES PIONEERING HYDROGEN AND SOLAR COMPANY TECH INFINITE

Thursday, December 2, 2021 - 11:03am

London, 2 December 2021- Compagnie Mercosur Grecemar ("CMG"), a Paris listed company, announced today it has agreed to the terms for the acquisition of renewable energy solution provider Tech Infinite.

Key Points: 
  • London, 2 December 2021- Compagnie Mercosur Grecemar ("CMG"), a Paris listed company, announced today it has agreed to the terms for the acquisition of renewable energy solution provider Tech Infinite.
  • The business has developed a standalone carbon neutral solution for mobile locations and commercial energy use, based upon a multi-fuel hydrogen approach.
  • The UK residential solar market is estimated to be worth between GBP140.4 billion and GBP300 billion over the next 10 years.
  • Tech Infinite's mission is to be a first mover, capture the UK residential solar market and become the leader for the next 25 years.

JSC Halyk Bank: Invitation to Participate in GDR Purchase Transaction

Thursday, December 2, 2021 - 8:02am

This Invitation to Participate in respect of the Bank's GDRs is being conducted concurrently with an invitation by the Bank to its holders of common shares (the "Shares") to purchase such shares (the "Share Purchase Transaction") on substantially identical terms to this Invitation to Participate.

Key Points: 
  • This Invitation to Participate in respect of the Bank's GDRs is being conducted concurrently with an invitation by the Bank to its holders of common shares (the "Shares") to purchase such shares (the "Share Purchase Transaction") on substantially identical terms to this Invitation to Participate.
  • The purpose of the GDR Purchase Transaction and the Share Purchase Transaction is to optimise the capital structure of the Bank.
  • Consequently, Offers to Participate in the GDR Purchase Transaction, when aggregated with offers to participate in the Share Purchase Transaction, will only be accepted up to the Maximum Acceptance Amount.
  • In the event that Offers to Participate in the GDR Purchase Transaction, when aggregated with offers to participate in the Share Purchase Transaction, exceed the Maximum Acceptance Amount, a pro rata reduction will be applied to all Offers to Participate (the "Pro-ration Factor").

2CRSi SA: Availability of the half-year financial report.

Wednesday, December 1, 2021 - 6:05pm

2CRSi SA: Availability of the half-year financial report.

Key Points: 
  • 2CRSi SA: Availability of the half-year financial report.
  • Strasbourg (France), 1 December 2021 - 2CRSi, a designer and manufacturer of high-performance, energy-efficient servers, announces today the availability of its half-year financial report.
  • 2CRSi announces that its half-year financial report for the 6-month period from March 1 to August 31, 2021 has been made available to the public today and filed with the French Financial Markets Authority (Autorit des Marchs Financiers).
  • The report includes the half-year 2021-22 consolidated financial statements, the highlights of the first half of the year, the statement by the person responsible for the half-year financial report as well as the Statutory Auditors' review report on the half-year consolidated financial statements.

BILENDI: Bilendi announces the completion of the the acquisition of the respondi group

Tuesday, November 30, 2021 - 5:09pm

Paris, November 30, 2021 - Bilendi, a European leader in research technology and data, announces the completion of the acquisition of the respondi Group following the fulfilment of the customary closing conditions.

Key Points: 
  • Paris, November 30, 2021 - Bilendi, a European leader in research technology and data, announces the completion of the acquisition of the respondi Group following the fulfilment of the customary closing conditions.
  • With this strategic move, Bilendi takes a significant step forward in its development and further strengthens its position in the top three European markets: Germany, France and the United Kingdom.
  • Founded in 2005 in Cologne, Germany, respondi is a European player dedicated to data collection for market research in Europe.
  • Following the acquisition of respondi, Bilendi will succeed in its target to achieve annual revenues of 50 million by 2023, on a pro forma basis [1] .

Société du Grand Paris : final terms serie 17 Issue of EUR 1,250,000,000 1.000 per cent. Notes due 26 November 2051

Thursday, November 25, 2021 - 2:04pm

Socit du Grand Paris : final terms serie 17 Issue of EUR 1,250,000,000 1.000 per cent.

Key Points: 
  • Socit du Grand Paris : final terms serie 17 Issue of EUR 1,250,000,000 1.000 per cent.
  • Notes due 26 November 2051
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • This document constitutes the Final Terms of the Notes described herein for the purposes of the Prospectus Regulation and must be read in conjunction with such Base Prospectus.
  • The Final Terms and the Base Prospectus will be available on the Issuer's website ( https://www.societedugrandparis.fr/publications-financieres-1870 ) and on the AMF's website ( www.amf-france.org ).

Société du Grand Paris : Final terms - Issue of EUR 1,750,000,000 0.300 per cent. Notes due 25 November 2031

Thursday, November 25, 2021 - 2:04pm

Socit du Grand Paris : Final terms - Issue of EUR 1,750,000,000 0.300 per cent.

Key Points: 
  • Socit du Grand Paris : Final terms - Issue of EUR 1,750,000,000 0.300 per cent.
  • Notes due 25 November 2031
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • This document constitutes the Final Terms of the Notes described herein for the purposes of the Prospectus Regulation and must be read in conjunction with such Base Prospectus.
  • The Final Terms and the Base Prospectus will be available on the Issuer's website ( https://www.societedugrandparis.fr/publications-financieres-1870 ) and on the AMF's website ( www.amf-france.org ).

Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research & Development

Monday, November 22, 2021 - 7:21pm

Dr. Burkhard Blank is an experienced leader in global drug development, medical and regulatory affairs, and pharmacovigilance with more than 25 years of industry experience.

Key Points: 
  • Dr. Burkhard Blank is an experienced leader in global drug development, medical and regulatory affairs, and pharmacovigilance with more than 25 years of industry experience.
  • He joins Pharnext from Acorda Therapeutics where he held the position of CMO and Head of Research & Development for the past six years.
  • Prior to this, Dr Blank served as CMO for several biopharmaceutical companies, including Boehringer Ingelheim, Herantis Pharma, and Mersana Therapeutics.
  • Dr. David Horn Solomon, Chief Executive Officer of Pharnext, commented: "I am delighted to welcome Burkhard to the team and look forward to working with him.